Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07464951) titled 'CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia' on March 4.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Stephan Grupp MD PhD
Condition:
Acute Myeloid Leukemia (AML)
Intervention:
Biological: Anti-CD123 LV redirected T cells (CART123)
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: April 1, 2026
Target Sample Size: 30
Countries of Recruitment:
United States
To know more, visit https://clinicaltr...